- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Venmax Drugs & Pharmaceuticals confirmed no deviation in the use of proceeds from its preferential issue for the quarter ended December 31, 2025. The company aimed to raise Rs. 20.05 Cr, with Rs. 9.99 Cr received from investors so far. Of the utilized funds, Rs. 3.79 Cr went towards working capital, and Rs. 0.19 Cr for general corporate purposes and business acquisition. This update provides clarity on fund deployment, assuring shareholders that the capital is being used as initially outlined.